Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma

Cancer

Volumn 94, Issue 12, 2002, Pages 3107-3114

  Wang, Jianzhou ^a   Buchholz, Thomas A ^a   Middleton, Lavinia P ^a   Allred, D Craig ^b   Tucker, Susan L ^a   Kuerer, Henry M ^a   Esteva, Francisco J ^a   Hortobagyi, Gabriel N ^a   Sahin, Aysegul A ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast carcinoma; Her2 neu; Mitosin; Mitotic activity; Neoadjuvant chemotherapy; Nuclear grade

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; TUMOR MARKER;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CELL ACTIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; MITOSIS INDEX; ONCOGENE NEU; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHROMOSOMAL PROTEINS, NON-HISTONE; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 0037096869     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10585     Document Type: Article

References (49)

1. Six year results of a multimodality treatment strategy for locally advanced breast cancer
2. Management of Stage III breast cancer with primary chemotherapy, surgery, and radiation therapy
3. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer
4. Prognostic factors in locally advanced noninflammatory breast cancer: Long-term results following primary chemotherapy
5. Results of neoadjuvant chemotherapy and radiation therapy in breast conserving treatment of 250 patients with all stages of infiltrative breast cancer
6. Induction chemotherapy followed by breast conservation for locally advanced breast cancer
7. Clinical course of breast cancer patients with complete pathologic primary and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
8. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more
9. Assessment of responses to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland
10. Histologic grade, elastosis, DNA ploidy and response to chemotherapy
11. Tumor aneuploidy, prognostic parameters and survival in primary breast cancer
12. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer: Clinical experience and parameters predicting outcome
13. A multivariate analysis of tumor biologic factors predicting response to cytotoxic treatment in advanced breast cancer
14. p53 and c-erbB-2 expression and response to preoperative chemotherapy in locally advanced breast carcinoma
15. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
16. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
17. ERBB2 overexpression in breast carcinomas: No positive correlation with complete pathologic response to preoperative highdose anthracycline-based chemotherapy
18. Expression of Bcl-2 but not Bax or p53 with in vitro resistance to a series of anticancer drugs in breast cancer
19. Role of p53 and Bcl-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy
20. Bcl-2 immunostaining: A way to finding unresponsive postmenopausal N+ breast cancer patients
21. Nuclear structure in cancer tissue
22. In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors
23. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18
24. Cell kinetics as a prognostic marker in locally advanced breast cancer
25. Pathologic predictors of tumor response to preoperative chemotherapy in patients with locally advanced cancer
26. Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry, an Eastern Cooperative Group study (2192)
27. Do DNA ploidy and S-phase fraction in primary tumor predict the response to chemotherapy in metastatic breast cancer?
28. Prediction of response to primary chemotherapy for operable breast cancer
29. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: A flow cytometry study on fine needle aspirates
30. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas
31. Characterization of a novel 350-kilodalton nuclear phosphoprotein that is specifically involved in mitotic-phase progression
32. Mitosin (a new proliferation marker) correlates with clinical outcome in nodenegative breast cancer
33. Biologic makers as predictors of clinical outcome from systemic therapy for primary operable breast cancer
34. Signal transduction. The hunt for Ras targets
35. Human breast cancer: Correlation of relapse and survival with the amplification of Her2-neu oncogene
36. c-erbB-2 in benign and malignant breast disease
37. Her-2/neu in node negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
38. Prognostic importance of c-erbB-2 expression in breast cancer
39. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
40. HER-2/neu oncogene protein and prognosis in breast cancer
41. Structure and expression of c-erbB-2 and EFG receptor gene in inflammatory and noninflammatory breast cancer: Prognostic significance
42. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer
43. Expression of c-erbB-oncoprotein: A prognostic indicator in human breast cancer
44. HER2/neu amplification and comedo type breast carcinoma
45. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
46. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
47. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
48. Influence of TP53 gene alteration and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer